Use of WB-MRI to Evaluate the Distribution of Tumour Burden after Initial Systemic Therapy in High Volume Metastatic Hormone-sensitive Prostate Cancer Patients

Purpose: Metastatic hormone-sensitive prostate cancer (mHSPC) can be classified as high or low volume on conventional imaging (CT and bone scan) [1]. However, the optimal imaging modality for evaluating response to treatment is yet to be determined. Whole body diffusion-weighted MRI (WB-DWI MRI) is more sensitive than conventional imaging at detecting bone metastases and assessing response to therapy [2]. Standard of care treatment for mHSPC is androgen deprivation (ADT) plus systemic therapy (androgen receptor targeted agent [ARTA] ± docetaxel chemotherapy).

Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: C. Thompson, N. Tunarui, A. Tree, A. Reid, C. Parker, J. Murray Source Type: research